Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 650 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $26.50 million which missed the analyst consensus estimate of $27.29 million by 2.91 percent. This is a 13.41 percent increase over sales of $23.36 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.